Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.
Since Nov 17, 2025
Transactions
109
Purchases
2
Sales
107
Purchase value
$3.31M
Sale value
$97.67M
Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.
Daniel N Swisher JRDirector
4Rule 10b5-1 plan disclosed
Filed Nov 13, 2026Period of report Nov 10, 20260001193125-26-460765
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleNov 10, 2026
Common StockF1
1,500
$74.07
$111.11K
0
Direct
Filing footnotes · 3
F1The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 3, 2026 in effect at the time of this transaction.
F2Fully exercisable.
F3The Reporting Person previously transferred 12,500 shares underlying the stock option to his ex-spouse. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.
Filed Nov 4, 2026Period of report Nov 2, 20260001193125-26-447906
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleNov 3, 2026
Common StockF2F4F1
8,617
$82.0198
$706.76K
14,480
Direct
SaleNov 3, 2026
Common StockF2F5F1
4,542
$82.6756
$375.51K
9,938
Direct
SaleNov 2, 2026
Common StockF2F3F1
11,841
$81.4183
$964.07K
9,938
Direct
Filing footnotes · 13
F1Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F10Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F11Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F12Represents the shares held by SNM 2026-2 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F13Fully exercisable.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.12 to $82.10 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.25 to $82.24 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $82.34 to $83.02 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F6Reflects a transfer of shares of Common Stock between direct and indirect accounts over which the Reporting Person has beneficial ownership. The transfer resulted only in a change in the form of the Reporting Person's beneficial ownership and is exempt from Section 16 pursuant to Rule 16a-13 under the Securities Exchange Act of 1934, as amended.
F7Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
F8Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
F9Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
Filed Nov 4, 2026Period of report Nov 2, 20260001193125-26-447899
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleNov 2, 2026
Common StockF2F3F1
6,657
$80.7326
$537.44K
5,622
Direct
SaleNov 2, 2026
Common StockF2F4F1
1,676
$81.5226
$136.63K
3,946
Direct
Filing footnotes · 5
F1Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 138 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the Reporting Person being appointed an officer of the Issuer, which was in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.15 to $81.12 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.17 to $82.07 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on January 29, 2028, subject to the Reporting Person's continued service.
Filed Oct 16, 2026Period of report Oct 15, 20260001193125-26-424350
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleOct 15, 2026
Common StockF1F2F5
6,654
$114.4751
$761.72K
1,057,889
IndirectJames N. Wilson and Pamela D. Wilson Trust
SaleOct 15, 2026
Common StockF1F3F5
3,046
$115.3895
$351.48K
1,054,843
IndirectJames N. Wilson and Pamela D. Wilson Trust
SaleOct 15, 2026
Common StockF1F4F5
300
$116.2967
$34.89K
1,054,543
IndirectJames N. Wilson and Pamela D. Wilson Trust
Filing footnotes · 5
F1This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.
F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.13 to $115.12 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.16 to $116.10 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.19 to $116.35 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
Filed Oct 5, 2026Period of report Oct 2, 20260001193125-26-414688
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleOct 2, 2026
Common StockF2F3F1
1,100
$114.5205
$125.97K
11,179
Direct
SaleOct 2, 2026
Common StockF2F4F1
2,086
$115.7298
$241.41K
9,093
Direct
SaleOct 2, 2026
Common StockF2F5F1
5,147
$116.585
$600.06K
3,946
Direct
Filing footnotes · 6
F1Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 138 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the Reporting Person being appointed an officer of the Issuer, which was in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.03 to $114.90 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.16 to $116.04 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.24 to $117.22 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F6Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on January 29, 2028, subject to the Reporting Person's continued service.
Filed Oct 5, 2026Period of report Oct 1, 20260001193125-26-414684
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleOct 2, 2026
Common StockF2F4F1
4,446
$115.697
$514.39K
10,427
Direct
SaleOct 2, 2026
Common StockF2F5F1
4,744
$116.5407
$552.87K
5,683
Direct
SaleOct 1, 2026
Common StockF2F3F1
810
$115.3985
$93.47K
5,683
Direct
Filing footnotes · 6
F1Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 10, 2026 in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.23 to $115.615 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.23 to $116.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.25 to $116.98 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Filed Oct 5, 2026Period of report Oct 1, 20260001193125-26-414674
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleOct 2, 2026
Common StockF2F4F1
15,843
$116.1233
$1.84M
18,682
Direct
SaleOct 2, 2026
Common StockF2F5F1
8,744
$116.5534
$1.02M
9,938
Direct
SaleOct 1, 2026
Common StockF2F3F1
413
$115.5373
$47.72K
9,938
Direct
Filing footnotes · 11
F1Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F10Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F11Fully exercisable.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.30 to $115.615 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.38 to $116.36 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.39 to $117.22 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F6Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
F7Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
F8Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F9Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
Filed Sep 18, 2026Period of report Sep 16, 20260001193125-26-395837
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleSep 16, 2026
Common StockF1F2
296
$100.82
$29.84K
3,946
Direct
Filing footnotes · 2
F1This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction.
F2Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 138 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
Filed Sep 16, 2026Period of report Sep 15, 20260001193125-26-393124
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleSep 15, 2026
Common StockF1F2F5
6,800
$110.2698
$749.83K
1,067,743
IndirectJames N. Wilson and Pamela D. Wilson Trust
SaleSep 15, 2026
Common StockF1F3F5
400
$110.8363
$44.33K
1,067,343
IndirectJames N. Wilson and Pamela D. Wilson Trust
SaleSep 15, 2026
Common StockF1F4F5
2,800
$111.7039
$312.77K
1,064,543
IndirectJames N. Wilson and Pamela D. Wilson Trust
Filing footnotes · 5
F1This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.
F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $109.66 to $110.64 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.665 to $111.095 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.70 to $111.705 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
Filed Sep 16, 2026Period of report Sep 14, 20260001193125-26-393125
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleSep 14, 2026
Common StockF2F3F1
7,812
$113.3206
$885.26K
7,871
Direct
SaleSep 14, 2026
Common StockF2F4F1
2,188
$114.1163
$249.69K
5,683
Direct
Filing footnotes · 5
F1Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 10, 2026 in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.81 to $113.72 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.92 to $114.50 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Filed Sep 3, 2026Period of report Sep 1, 20260001193125-26-382456
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleSep 2, 2026
Common StockF8F9F7
23,600
$109.3506
$2.58M
38,975
Direct
SaleSep 2, 2026
Common StockF8F10F7
23,770
$110.7004
$2.63M
15,205
Direct
SaleSep 2, 2026
Common StockF8F11F7
1,537
$111.3733
$171.18K
13,668
Direct
SaleSep 2, 2026
Common StockF8F12F7
974
$112.3966
$109.47K
12,694
Direct
SaleSep 2, 2026
Common StockF8F13F7
1,606
$113.7187
$182.63K
11,088
Direct
SaleSep 2, 2026
Common StockF8F14F7
5,621
$114.5779
$644.04K
5,467
Direct
SaleSep 2, 2026
Common StockF8F15F7
1,225
$115.4395
$141.41K
4,242
Direct
Filing footnotes · 16
F1The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.
F10Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.06 to $111.03 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F11Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.06 to $111.945 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F12Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.08 to $113.03 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F13Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.11 to $114.09 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F14Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.24 to $115.195 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F15Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.255 to $115.57 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F16Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on January 29, 2028, subject to the Reporting Person's continued service.
F2In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F3Includes 199 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F4Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
F5These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
F6The closing price on September 1, 2026 was used to calculate the withholding obligation.
F7Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F8This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction.
F9Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $108.97 to $109.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Filed Sep 3, 2026Period of report Sep 1, 20260001193125-26-382474
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleSep 1, 2026
Common StockF2F3F1
11,730
$113.9351
$1.34M
23,025
Direct
SaleSep 1, 2026
Common StockF2F4F1
10,989
$114.7118
$1.26M
12,036
Direct
SaleSep 1, 2026
Common StockF2F5F1
2,281
$115.6118
$263.71K
9,755
Direct
Filing footnotes · 17
F1Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F10The closing price on September 1, 2026 was used to calculate the withholding obligation.
F11Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F12Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
F13Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
F14Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F15Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F16Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F17Fully exercisable.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.36 to $114.34 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.365 to $115.295 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.37 to $115.82 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F6The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.
F7In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F8Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
F9These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
Filed Aug 28, 2026Period of report Aug 26, 20260001193125-26-374607
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleAug 26, 2026
Common StockF2
26,685
$122.5471
$3.27M
0
Direct
Filing footnotes · 3
F1These shares were withheld by the Issuer in order to cover the exercise price in connection with the net exercise of stock options reported herein.
F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $122.50 to $122.80 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Filed Aug 27, 2026Period of report Aug 25, 20260001193125-26-371388
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleAug 25, 2026
Common StockF2F3F1
25,085
$125.4676
$3.15M
15,625
Direct
SaleAug 25, 2026
Common StockF2F4F1
5,870
$126.0588
$739.97K
9,755
Direct
Filing footnotes · 10
F1Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F10Fully exercisable.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $125.00 to $125.98 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $126.00 to $126.23 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
F6Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
F7Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F8Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F9Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
Filed Aug 20, 2026Period of report Aug 18, 20260001193125-26-359255
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleAug 18, 2026
Common StockF1F2
4,984
$117.4716
$585.48K
1,232,161
IndirectHeld by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust
SaleAug 18, 2026
Common StockF1F3
91,167
$118.2376
$10.78M
1,140,994
IndirectHeld by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust
SaleAug 18, 2026
Common StockF1F4
7,055
$118.8817
$838.71K
1,133,939
IndirectHeld by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust
SaleAug 18, 2026
Common StockF1F5
400
$119.6381
$47.86K
1,133,539
IndirectHeld by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust
Filing footnotes · 5
F1This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on May 11, 2026 in effect at the time of this transaction.
F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.595 to $117.59. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $117.60 to $118.595. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $118.60 to $119.345. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
F5Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $119.605 to $119.6775. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
Filed Aug 18, 2026Period of report Aug 17, 20260001193125-26-355560
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleAug 17, 2026
Common StockF2F3
10,000
$116.2572
$1.16M
39,716
IndirectGary Charles Robb TTE Robb Revocable Trust
Filing footnotes · 5
F1Includes 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.00 to $116.54 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
F3These shares are held by Gary Charles Robb TTE Robb Revocable Trust of which the Reporting Person is trustee.
F4These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.
F5These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.
Filed Aug 18, 2026Period of report Aug 14, 20260001193125-26-355563
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleAug 14, 2026
Common StockF2F1
3,664
$114.49
$419.49K
9,755
Direct
Filing footnotes · 8
F1Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
F3Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
F4Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
F5Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F6Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F7Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
Filed Aug 18, 2026Period of report Aug 14, 20260001193125-26-355562
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleAug 14, 2026
Common StockF1F2F5
3,053
$110.4949
$337.34K
1,081,490
IndirectJames N. Wilson and Pamela D. Wilson Trust
SaleAug 14, 2026
Common StockF1F3F5
4,668
$111.4425
$520.21K
1,076,822
IndirectJames N. Wilson and Pamela D. Wilson Trust
SaleAug 14, 2026
Common StockF1F4F5
2,279
$112.6398
$256.71K
1,074,543
IndirectJames N. Wilson and Pamela D. Wilson Trust
Filing footnotes · 5
F1This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.
F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.00 to $110.98 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.01 to $112.00 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.51 to $112.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
Filed Aug 12, 2026Period of report Aug 10, 20260001193125-26-346951
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleAug 10, 2026
Common StockF2F3F1
1,031
$114.5182
$118.07K
9,755
Direct
Filing footnotes · 9
F1Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.50 to $114.58 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
F5Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
F6Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F7Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F8Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
Filed Aug 12, 2026Period of report Aug 10, 20260001193125-26-346942
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleAug 10, 2026
Common StockF2F3F1
11,530
$113.1772
$1.30M
8,755
Direct
SaleAug 10, 2026
Common StockF2F4F1
4,770
$114.0371
$543.96K
3,985
Direct
Filing footnotes · 5
F1Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.80 to $113.75 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.98 to $114.24 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Filed Aug 6, 2026Period of report Aug 4, 20260001193125-26-338637
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleAug 4, 2026
Common StockF2F3F1
3,700
$113.1248
$418.56K
3,985
Direct
Filing footnotes · 4
F1Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.92 to $113.455 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Filed Aug 5, 2026Period of report Aug 3, 20260001193125-26-335617
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleAug 3, 2026
Common StockF2F3F1
20,305
$114.7045
$2.33M
9,755
Direct
Filing footnotes · 9
F1Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.49 to $115.00 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
F5Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
F6Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F7Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F8Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
Filed Aug 5, 2026Period of report Aug 3, 20260001193125-26-335605
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleAug 3, 2026
Common StockF1
1,540
$114.16
$175.81K
5,495
Direct
Filing footnotes · 1
F1Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
Filed Aug 3, 2026Period of report Jul 30, 20260001193125-26-330668
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJul 30, 2026
Common StockF2F3F1
4,200
$105.5352
$443.25K
91,930
Direct
SaleJul 30, 2026
Common StockF2F4F1
8,956
$106.9553
$957.89K
82,974
Direct
SaleJul 30, 2026
Common StockF2F1
400
$108.46
$43.38K
82,574
Direct
SaleJul 30, 2026
Common StockF2F5F1
2,202
$110.0283
$242.28K
80,372
Direct
SaleJul 30, 2026
Common StockF2F1
600
$110.95
$66.57K
79,772
Direct
SaleJul 30, 2026
Common StockF2F6F1
4,700
$113.1789
$531.94K
75,072
Direct
SaleJul 30, 2026
Common StockF2F7F1
15,477
$114.9601
$1.78M
59,595
Direct
SaleJul 30, 2026
Common StockF2F8F1
14,222
$115.8669
$1.65M
45,373
Direct
SaleJul 30, 2026
Common StockF2F9F1
7,089
$116.9561
$829.10K
38,284
Direct
SaleJul 30, 2026
Common StockF2F10F1
8,267
$117.9329
$974.95K
30,017
Direct
SaleJul 30, 2026
Common StockF2F11F1
4,783
$118.7346
$567.91K
25,234
Direct
SaleJul 30, 2026
Common StockF2F12F1
8,103
$119.9481
$971.94K
17,131
Direct
SaleJul 30, 2026
Common StockF2F13F1
1,001
$120.6749
$120.80K
16,130
Direct
Filing footnotes · 14
F1Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F10Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $117.41 to $118.39 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F11Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $118.42 to $119.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F12Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $119.42 to $120.41 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F13Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $120.49 to $120.84 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F14Fully exercisable.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 12, 2025 in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $105.305 to $106.2 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $106.75 to $107.195 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $109.71 to $110.42 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F6Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.96 to $113.89 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F7Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.305 to $115.30 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F8Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.35 to $116.27 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F9Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.35 to $117.3 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Filed Jul 17, 2026Period of report Jul 15, 20260001193125-26-308061
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJul 15, 2026
Common StockF1F2F6
1,079
$86.7777
$93.63K
1,093,464
IndirectJames N. Wilson and Pamela D. Wilson Trust
SaleJul 15, 2026
Common StockF1F3F6
3,969
$87.7356
$348.22K
1,089,495
IndirectJames N. Wilson and Pamela D. Wilson Trust
SaleJul 15, 2026
Common StockF1F4F6
2,974
$88.8105
$264.12K
1,086,521
IndirectJames N. Wilson and Pamela D. Wilson Trust
SaleJul 15, 2026
Common StockF1F5F6
1,978
$89.4881
$177.01K
1,084,543
IndirectJames N. Wilson and Pamela D. Wilson Trust
Filing footnotes · 6
F1This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.
F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $86.20 to $87.18 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $87.23 to $88.20 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $88.24 to $89.17 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $89.31 to $89.665 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F6Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
Filed Jul 17, 2026Period of report Jul 15, 20260001193125-26-308058
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJul 15, 2026
Common StockF2F3F1
7,919
$86.776
$687.18K
48,211
Direct
SaleJul 15, 2026
Common StockF2F4F1
28,460
$87.8863
$2.50M
19,751
Direct
SaleJul 15, 2026
Common StockF2F5F1
3,520
$88.3016
$310.82K
16,231
Direct
SaleJul 15, 2026
Common StockF2F6F1
101
$89.4282
$9.03K
16,130
Direct
Filing footnotes · 7
F1Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 12, 2025 in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $86.20 to $87.19 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $87.23 to $88.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $88.24 to $89.07 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F6Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $89.25 to $89.43 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Filed Jul 8, 2026Period of report Jul 7, 20260001193125-26-298865
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJul 7, 2026
Common StockF2F3F1
19,048
$93.1059
$1.77M
4,937
Direct
SaleJul 7, 2026
Common StockF2F4F1
952
$93.5383
$89.05K
3,985
Direct
Filing footnotes · 5
F1Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $92.50 to $93.43 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $93.52 to $93.665 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Filed Jul 6, 2026Period of report Jul 1, 20260001193125-26-296296
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJul 1, 2026
Common StockF2F3F1
11,024
$87.3349
$962.78K
23,731
Direct
SaleJul 1, 2026
Common StockF2F4F1
2,801
$88.5127
$247.92K
20,930
Direct
SaleJul 1, 2026
Common StockF2F5F1
11,175
$89.3094
$998.03K
9,755
Direct
Filing footnotes · 11
F1Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F10Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F11Fully exercisable.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $86.95 to $87.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $87.98 to $88.97 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $89.09 to $89.37 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F6Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
F7Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
F8Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F9Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
Filed Jun 18, 2026Period of report Jun 17, 20260001193125-26-275963
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJun 17, 2026
Common StockF1
20,000
$84.5253
$1.69M
26,147
IndirectThe Black Dog Private Foundation
Filing footnotes · 1
F1Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $84.44 to $85.11. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
Filed Jun 18, 2026Period of report Jun 16, 20260001193125-26-275964
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJun 16, 2026
Common StockF1F2F4
4,177
$82.6948
$345.42K
1,100,366
IndirectJames N. Wilson and Pamela D. Wilson Trust
SaleJun 16, 2026
Common StockF1F3F4
5,823
$83.5708
$486.63K
1,094,543
IndirectJames N. Wilson and Pamela D. Wilson Trust
Filing footnotes · 4
F1This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.
F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $82.13 to $83.125 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $83.16 to $83.935 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
Filed Jun 17, 2026Period of report Jun 15, 20260001193125-26-274224
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJun 15, 2026
Common StockF2F3F1
9,434
$80.0216
$754.92K
46,696
Direct
SaleJun 15, 2026
Common StockF2F4F1
11,081
$80.9424
$896.92K
35,615
Direct
SaleJun 15, 2026
Common StockF2F5F1
19,483
$81.8092
$1.59M
16,132
Direct
SaleJun 15, 2026
Common StockF2F1
2
$82.45
$164.90
16,130
Direct
Filing footnotes · 6
F1Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 12, 2025 in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.40 to $80.39 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.40 to $81.39 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.40 to $82.18 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Filed Jun 4, 2026Period of report Jun 2, 20260001193125-26-257618
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJun 2, 2026
Common StockF2F3F1
20,000
$70.60
$1.41M
3,985
Direct
Filing footnotes · 4
F1Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.44 to $70.86 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Filed Jun 3, 2026Period of report Jun 1, 20260001193125-26-256013
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJun 1, 2026
Common StockF2F3F1
21,069
$70.1068
$1.48M
12,908
Direct
SaleJun 1, 2026
Common StockF2F4F1
3,931
$70.7462
$278.10K
8,977
Direct
Filing footnotes · 16
F1Includes 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F10Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F11Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
F12Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
F13Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F14Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F15Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F16Fully exercisable.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $69.49 to $70.48 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.49 to $70.95 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 1, 2026.
F6In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F7Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
F8These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
F9The closing price on June 1, 2026 was used to calculate the withholding obligation.
Filed Jun 3, 2026Period of report Jun 1, 20260001193125-26-256011
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJun 1, 2026
Common StockF2F3F1
40,000
$70.0001
$2.80M
15,257
Direct
Filing footnotes · 10
F1Includes 775 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F10Fully exercisable.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 12, 2025 in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.00 to $70.01 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 1, 2026.
F5In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F6Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
F7These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
F8The closing price on June 1, 2026 was used to calculate the withholding obligation.
F9Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
Joseph K BelanoffDirector · Chief Executive Officer
4Rule 10b5-1 plan disclosed
Filed Jun 2, 2026Period of report May 29, 20260001193125-26-253459
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJun 1, 2026
Common StockF6F1
12,837
$69.74
$895.25K
2,565,489
IndirectJoseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02
Filing footnotes · 6
F1Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
F2Transfer of shares without consideration to the Joseph K. Belanoff 2026 Grantor Retained Annuity Trust.
F3Shares are held by Joseph K. Belanoff 2026 Grantor Retained Annuity Trust, of which the Reporting Person is the trustee.
F4Transfer of shares without consideration to the Katherine A. Blenko 2026 Grantor Retained Annuity Trust.
F5Shares are held by Katherine A. Blenko 2026 Grantor Retained Annuity Trust, of which the spouse of the Reporting Person is the trustee.
F6This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.
Filed May 29, 2026Period of report May 27, 20260001193125-26-248977
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleMay 27, 2026
Common StockF1
5,000
$65.00
$325.00K
6,230
Direct
Filing footnotes · 1
F1Includes 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
Filed May 29, 2026Period of report May 27, 20260001193125-26-248967
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleMay 27, 2026
Common StockF2F3F1
54,575
$65.3711
$3.57M
29,402
Direct
SaleMay 27, 2026
Common StockF2F4F1
20,425
$66.1599
$1.35M
8,977
Direct
Filing footnotes · 10
F1Includes 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F10Fully exercisable.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $65.00 to $65.99 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $66.00 to $66.50 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
F6Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
F7Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F8Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F9Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
Filed May 7, 2026Period of report May 5, 20260001193125-26-212118
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleMay 5, 2026
Common StockF2F3F1
20,000
$51.83
$1.04M
2,231
Direct
Filing footnotes · 4
F1Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $51.60 to $52.05 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Joseph K BelanoffDirector · Chief Executive Officer
4Rule 10b5-1 plan disclosed
Filed May 5, 2026Period of report May 1, 20260001193125-26-206540
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleMay 1, 2026
Common StockF1F2F3
40,000
$50.0965
$2.00M
2,878,326
IndirectJoseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02
Filing footnotes · 3
F1This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.
F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $50.00 to $50.35 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F3Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
Filed Apr 8, 2026Period of report Apr 7, 20260001193125-26-148497
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleApr 7, 2026
Common StockF2F3F1
20,000
$40.97
$819.40K
2,231
Direct
Filing footnotes · 4
F1Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $40.85 to $41.30 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Joseph K BelanoffDirector · Chief Executive Officer
4Rule 10b5-1 plan disclosed
Filed Mar 27, 2026Period of report Mar 25, 20260001193125-26-129143
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleMar 25, 2026
Common StockF1F2F3
26,198
$50.0735
$1.31M
2,918,326
IndirectJoseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02
Filing footnotes · 3
F1This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.
F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $50.00 to $50.32 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F3Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
Filed Mar 24, 2026Period of report Mar 20, 20260001193125-26-122136
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleMar 20, 2026
Common StockF2F3F1
11,767
$36.01
$423.73K
2,231
Direct
Filing footnotes · 4
F1Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $35.97 to $36.24 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Filed Mar 19, 2026Period of report Mar 17, 20260001201715-26-000007
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseMar 17, 2026
Common StockF1
75,782
$33.0022
$2.50M
1,122,413
Direct
PurchaseMar 17, 2026
Common StockF2
24,218
$33.5633
$812.84K
1,146,631
Direct
Filing footnotes · 4
F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $32.43 to $33.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $33.44 to $33.68 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.
F4Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust.
Filed Mar 6, 2026Period of report Mar 4, 20260001193125-26-096653
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleMar 4, 2026
Common StockF2F3F1
8,233
$35.9949
$296.35K
2,231
Direct
Filing footnotes · 4
F1Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $35.97 to $36.05 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Filed Feb 5, 2026Period of report Feb 3, 20260001193125-26-039717
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleFeb 3, 2026
Common StockF1F2
20,000
$40.8667
$817.33K
1,235
Direct
Filing footnotes · 3
F1This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $40.71 to $41.2804 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Filed Jan 8, 2026Period of report Jan 6, 20260001193125-26-008023
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJan 6, 2026
Common StockF1F2
20,000
$35.1828
$703.66K
1,235
Direct
Filing footnotes · 3
F1This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $34.96 to $35.50 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Filed Dec 3, 2025Period of report Dec 1, 20250001193125-25-307282
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleDec 2, 2025
Common StockF6F7
19,360
$80.0499
$1.55M
1,875
Direct
SaleDec 2, 2025
Common StockF6
640
$80.875
$51.76K
1,235
Direct
Filing footnotes · 8
F1The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on December 1, 2025.
F2In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F3Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
F4Represents the shares held by The Lake Bainwood Living Trust of which the Reporting Person is a co-trustee.
F5Transfer of shares without consideration to the Reporting Person.
F6This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
F7Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.78 to $80.68 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Filed Dec 3, 2025Period of report Dec 1, 20250001193125-25-307251
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleDec 1, 2025
Common StockF2F3F1
20,000
$79.5245
$1.59M
7,904
Direct
Filing footnotes · 12
F1Includes 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 228 underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F10Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F11Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F12Fully exercisable.
F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.40 to $79.81 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on December 1, 2025.
F5In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F6Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
F7These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
F8The closing price on December 1, 2025 was used to calculate the withholding obligation.
F9Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
Filed Dec 3, 2025Period of report Dec 1, 20250001193125-25-307229
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleDec 1, 2025
Common StockF2F3F1
5,000
$79.5263
$397.63K
10,277
Direct
Filing footnotes · 9
F1Includes 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction.
F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.40 to $79.73 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on December 1, 2025.
F5In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F6Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
F7These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
F8The closing price on December 1, 2025 was used to calculate the withholding obligation.
Joseph K BelanoffDirector · Chief Executive Officer
4Rule 10b5-1 plan disclosed
Filed Dec 3, 2025Period of report Dec 1, 20250001193125-25-307204
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleDec 1, 2025
Common StockF1F2F3
40,000
$79.7699
$3.19M
2,701,370
IndirectJoseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02
Filing footnotes · 3
F1This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.
F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.65 to $79.97 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F3Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.